Full Breakdown
Johns Hopkins Develops Intranasal DNA Vaccine for Tuberculosis
4/8/2026, 8:07:24 PM
Innovative Vaccine Approach
Researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have developed a novel therapeutic DNA vaccine aimed at combating tuberculosis (TB). This vaccine, administered intranasally, targets drug-tolerant bacterial "persisters" that contribute to treatment failure and disease relapse. The World Health Organization (WHO) estimates that approximately 2 billion people globally carry a latent TB infection, with over 10 million developing active TB in 2024, resulting in 1.2 million deaths. Current treatment regimens are lengthy and often difficult to complete, necessitating the development of new therapeutic strategies.
Mechanism of Action
The vaccine combines two genes, rel Mtb and Mip3?, to enhance immune response against TB. According to Styliani Karanika, M.D., the lead author of the study, the fusion of these genes produces a signal that attracts immature dendritic cells, which are crucial for presenting TB proteins to T cells. This process is designed to generate localized T-cell immunity in the lungs, where TB infection occurs, while also eliciting systemic immune responses. In mouse studies, the vaccine demonstrated increased recruitment and activation of dendritic cells, leading to robust immune responses involving both CD4 and CD8 T cells.
Promising Preclinical Results
In studies involving rhesus macaques, the intranasal DNA vaccine elicited significant TB-specific immune responses in both the bloodstream and airways, akin to those observed in mice. These immune responses persisted for at least six months, indicating potential durability. However, Karanika emphasized that these studies focused solely on immune responses and did not assess protection against actual TB infection. Further research is required before advancing to human clinical trials.
Broader Implications
The findings suggest a shift towards immunotherapy targeting TB persisters, rather than relying solely on antibiotics to eliminate actively growing bacteria. The stability and efficient production of DNA vaccines could make them a viable option for future TB treatment strategies. The research was supported by various federal grants and awards from organizations including the National Institutes of Health and the Gilead HIV Research Scholar Award.
Official Statements & Responses
Karanika noted, “Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster, reduced lung inflammation, and prevented relapse after treatment ended.” This underscores the vaccine's potential to enhance existing treatment protocols for TB.
Criticism & Opposition
While the study presents promising results, some experts caution that the vaccine's efficacy against actual TB infections remains untested. The reliance on animal models may not fully translate to human responses, necessitating further validation in clinical settings.
What's Next
The research team plans to conduct additional preclinical studies to evaluate the vaccine's protective effects against TB before initiating human clinical trials. The ongoing exploration of this innovative approach could significantly impact TB treatment and management in the future.
